Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

NCT00046683 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

284

Enrollment

INDUSTRY

Sponsor class

Conditions

B Cell Chronic Lymphocytic Leukemia

Interventions

DRUG: alemtuzumab

Sponsor

Genzyme, a Sanofi Company